Using Health AI Platforms to Bridge Gaps in Patient Care with Matt Blosl DexCare TRANSCRIPT
Release Date: 05/14/2026
Using Health AI Platforms to Bridge Gaps in Patient Care with Matt Blosl DexCare TRANSCRIPT
Empowered Patient Podcast
Matt Blosl, CEO of DexCare, has a core mission to help large health systems use AI responsibly to attract patients and work with them to get appropriate care. While AI's data-processing capabilities are transformative, its use in clinical recommendations remains in its early stages, constrained by fragmented data and the limited availability of validated diagnoses. Matt advises healthcare leaders to adopt a problem-first approach to AI implementation and to use technology to drive significant change rather than just incremental improvements to existing workflows. Matt explains, "Artificial...
info_outline
Using Health AI Platforms to Bridge Gaps in Patient Care with Matt Blosl DexCare
Empowered Patient Podcast
Matt Blosl, CEO of DexCare, has a core mission to help large health systems use AI responsibly to attract patients and work with them to get appropriate care. While AI's data-processing capabilities are transformative, its use in clinical recommendations remains in its early stages, constrained by fragmented data and the limited availability of validated diagnoses. Matt advises healthcare leaders to adopt a problem-first approach to AI implementation and to use technology to drive significant change rather than just incremental improvements to existing workflows. Matt explains, "Artificial...
info_outline
Next Generation Bispecific Antibody Drug Conjugates Improves Targeting of Solid Tumors with Dr. Mayank Gandhi NEOK Bio TRANSCRIPT
Empowered Patient Podcast
Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity. NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank...
info_outline
Next Generation Bispecific Antibody Drug Conjugates Improves Targeting of Solid Tumors with Dr. Mayank Gandhi NEOK Bio
Empowered Patient Podcast
Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity. NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank...
info_outline
How Generative Vision Language AI is Transforming Radiology with Louis Blankemeier Cognita TRANSCRIPT
Empowered Patient Podcast
Louis Blankemeier, CEO and Co-Founder of Cognita, describes the significant gap between the number of radiologists and the rising volume and types of medical imaging that need to be reviewed. The Cognita generative visual language model is an advancement over earlier radiology AI applications that were designed to flag single findings. This integrated approach emulates a radiologist by analyzing complex images and generating full draft radiology reports, demonstrating reduced time per case, increased detection of critical findings, and decreased cognitive burden on radiologists....
info_outline
How Generative Vision Language AI is Transforming Radiology with Louis Blankemeier Cognita
Empowered Patient Podcast
Louis Blankemeier, CEO and Co-Founder of Cognita, describes the significant gap between the number of radiologists and the rising volume and types of medical imaging that need to be reviewed. The Cognita generative visual language model is an advancement over earlier radiology AI applications that were designed to flag single findings. This integrated approach emulates a radiologist by analyzing complex images and generating full draft radiology reports, demonstrating reduced time per case, increased detection of critical findings, and decreased cognitive burden on radiologists....
info_outline
Virtual Physical Therapy Matches In-Clinic Outcomes While Expanding Access and Convenience with Dr. Ashok Gupta Theranow TRANSCRIPT
Empowered Patient Podcast
Dr. Ashok Gupta, CEO and Founder of Theranow, highlights the growing demand for physical therapy and the challenges patients face in accessing care. The Theranow telehealth solution uses technologies such as computer vision and AI to enhance the effectiveness and efficiency of virtual care and to measure and document progress to support the clinician's work with the patient. Virtual physical therapy is demonstrating outcomes equal to in-person care and showing higher patient engagement and compliance, driven by the convenience of scheduling and remote monitoring tools. Ashok explains,...
info_outline
Virtual Physical Therapy Matches In-Clinic Outcomes While Expanding Access and Convenience with Dr. Ashok Gupta Theranow
Empowered Patient Podcast
Dr. Ashok Gupta, CEO and Founder of Theranow, highlights the growing demand for physical therapy and the challenges patients face in accessing care. The Theranow telehealth solution uses technologies such as computer vision and AI to enhance the effectiveness and efficiency of virtual care and to measure and document progress to support the clinician's work with the patient. Virtual physical therapy is demonstrating outcomes equal to in-person care and showing higher patient engagement and compliance, driven by the convenience of scheduling and remote monitoring tools. Ashok explains,...
info_outline
Enzyme Replacement Therapy for Sanfilippo Syndrome Type B with Dr. Javier Szwarcberg Spruce Biosciences TRANSCRIPT
Empowered Patient Podcast
Dr. Javier Szwarcberg, CEO of Spruce Biosciences, is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children. The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain. The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier...
info_outline
Enzyme Replacement Therapy for Sanfilippo Syndrome Type B with Dr. Javier Szwarcberg Spruce Biosciences
Empowered Patient Podcast
Dr. Javier Szwarcberg, CEO of Spruce Biosciences, is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children. The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain. The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier...
info_outlineMatt Blosl, CEO of DexCare, has a core mission to help large health systems use AI responsibly to attract patients and work with them to get appropriate care. While AI's data-processing capabilities are transformative, its use in clinical recommendations remains in its early stages, constrained by fragmented data and the limited availability of validated diagnoses. Matt advises healthcare leaders to adopt a problem-first approach to AI implementation and to use technology to drive significant change rather than just incremental improvements to existing workflows.
Matt explains, "Artificial intelligence is interesting. We're still in what I consider to be the Gold Rush phase of a new technology. Certainly one as disruptive as this. So I think a lot of our clients are still trying to figure out what it means. From my perspective, you said it very well. Google or the internet was kind of our first foray into providing patients more access before they even seek care or before they go in to receive care. And what I see right now is that the AI platforms are kind of the next level of that. The richness of the information is greater. And so patients are coming in more informed, and they can feel comfortable making decisions even more than they could with Google. That's clear in terms of how it's impacting the patients. I think the health systems are still trying to get their arms wrapped around what the appropriate use of AI across the enterprise is."
"Now, when it comes to making treatment recommendations, I still think we're in the early stages. There are still many hallucinations. The data sources we're pulling from are still fragmented. Data hygiene and some of that data are not always accurate. So I think there's going to have to be a lot of evolution in how we manage the data and improve interoperability, so that all of the data can start to talk to one another, and we can really have a complete picture before these platforms can really impact care."
#DexCare #AIinHealthcare #DigitalHealth #HealthSystems #ClinicalAI #HealthcareInnovation #PatientAccess #DigitalFrontDoor #CareOrchestration #HealthIT #Interoperability #DataQuality #PrecisionMedicine #PersonalizedCare #ClinicianExperience #HealthcareLeadership #DigitalTransformation #HealthTech #HospitalOperations #CallCenterAutomation #EmergencyMedicine
